Mester J - Search Results

1

Mester J, Charis E. Mester J, et al. Handb Clin Neurol. 2015;132:129-37. doi: 10.1016/B978-0-444-62702-5.00009-3. Handb Clin Neurol. 2015. PMID: 26564076 Review.

2

Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome.

Mester J, Eng C. Mester J, et al. Genet Med. 2012 Sep;14(9):819-22. doi: 10.1038/gim.2012.51. Epub 2012 May 17. Genet Med. 2012. PMID: 22595938 Free PMC article.

3

Cognitive characteristics of PTEN hamartoma tumor syndromes.

Busch RM, Chapin JS, Mester J, Ferguson L, Haut JS, Frazier TW, Eng C. Busch RM, et al. Among authors: mester j. Genet Med. 2013 Jul;15(7):548-53. doi: 10.1038/gim.2013.1. Epub 2013 Mar 7. Genet Med. 2013. PMID: 23470840 Free PMC article.

4

Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.

Mester JL, Zhou M, Prescott N, Eng C. Mester JL, et al. Urology. 2012 May;79(5):1187.e1-7. doi: 10.1016/j.urology.2011.12.025. Epub 2012 Mar 3. Urology. 2012. PMID: 22381246 Free PMC article.

5

Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Ngeow J, et al. Among authors: mester jl. J Clin Oncol. 2014 Jun 10;32(17):1818-24. doi: 10.1200/JCO.2013.53.6656. Epub 2014 Apr 28. J Clin Oncol. 2014. PMID: 24778394 Free PMC article.

6

Lifetime cancer risks in individuals with germline PTEN mutations.

Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Tan MH, et al. Among authors: mester jl. Clin Cancer Res. 2012 Jan 15;18(2):400-7. doi: 10.1158/1078-0432.CCR-11-2283. Clin Cancer Res. 2012. PMID: 22252256 Free PMC article.

7

Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.

Mester JL, Tilot AK, Rybicki LA, Frazier TW 2nd, Eng C. Mester JL, et al. Eur J Hum Genet. 2011 Jul;19(7):763-8. doi: 10.1038/ejhg.2011.20. Epub 2011 Feb 23. Eur J Hum Genet. 2011. PMID: 21343951 Free PMC article.

8

PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?

Mester JL, Moore RA, Eng C. Mester JL, et al. Oncologist. 2013;18(10):1083-90. doi: 10.1634/theoncologist.2013-0174. Epub 2013 Sep 13. Oncologist. 2013. PMID: 24037976 Free PMC article.

9

Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Ngeow J, He X, Mester JL, Lei J, Romigh T, Orloff MS, Milas M, Eng C. Ngeow J, et al. Among authors: mester jl. J Clin Endocrinol Metab. 2012 Dec;97(12):E2320-7. doi: 10.1210/jc.2012-2944. Epub 2012 Oct 12. J Clin Endocrinol Metab. 2012. PMID: 23066114 Free PMC article.

10

A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C. Tan MH, et al. Among authors: mester j. Am J Hum Genet. 2011 Jan 7;88(1):42-56. doi: 10.1016/j.ajhg.2010.11.013. Epub 2010 Dec 30. Am J Hum Genet. 2011. PMID: 21194675 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

398 results

Search Page